QuidelOrtho Corporation Acquires LEX Diagnostics to Enhance Molecular Diagnostics Offerings

QuidelOrtho Corporation Completes Acquisition of LEX Diagnostics

QuidelOrtho Corporation, a prominent player in the field of in vitro diagnostics, announced today the successful acquisition of LEX Diagnostics for approximately $100 million in cash. This strategic move is poised to enhance QuidelOrtho's capabilities in molecular diagnostics, particularly in the realm of point-of-care testing.

The focus of this acquisition is the LEX VELO System, a groundbreaking platform that has recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA), along with a CLIA waiver. This system is designed for rapid molecular diagnostics, facilitating highly sensitive multiplex RT-PCR testing for illnesses such as Influenza A, Influenza B, and COVID-19, all from a single swab sample. Remarkably, the LEX VELO System can produce accurate results in just six to ten minutes, significantly expediting clinical decision-making in various healthcare environments.

Brian J. Blaser, the President and CEO of QuidelOrtho, expressed optimism about the potential of the LEX VELO System, stating, "This ultra-fast PCR platform is designed to deliver lab-quality results in mere minutes and fits seamlessly into point-of-care workflows. It empowers providers to act faster, make informed decisions, and ultimately improve patient outcomes."

The integration of LEX into QuidelOrtho’s portfolio is not merely a financial transaction; it reflects the company’s commitment to advancing diagnostic solutions across the entire continuum of care, from point-of-care facilities to hospitals and clinics. Ed Farrell, CEO of LEX, shared a similar vision, emphasizing the importance of this acquisition in redefining possibilities within point-of-care molecular diagnostics.

QuidelOrtho anticipates commencing the U.S. commercial launch of the LEX VELO System later in the year, with plans for global expansion subject to local regulatory approvals. This move is anticipated to not only enhance QuidelOrtho's molecular diagnostics offerings but also allow the company to maintain its leadership in immunoassay and clinical chemistry markets.

The company's commitment to improving patient outcomes through fast and reliable diagnostic solutions is more critical than ever in today’s healthcare landscape. As QuidelOrtho prepares for the rollout of the LEX VELO System, the integration of this cutting-edge technology is set to empower healthcare providers worldwide, enabling them to respond swiftly to patient needs.

With this acquisition, QuidelOrtho continues to solidify its position as a leader in the diagnostic field, leveraging innovative technologies to bring advanced diagnostics closer to patients in various care settings. As they move forward, QuidelOrtho remains dedicated to advancing diagnostics and ultimately building a healthier future for all.

For further insights and updates on QuidelOrtho’s endeavours, interested parties can visit their official website or follow them on LinkedIn, Facebook, and X.